What is the 13F Pro Quality Score for HTFL?

13F Pro ranks Heartflow, Inc. (HTFL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HTFL's current score at https://13fpro.ai/research/HTFL (free sign-up required for the full ranking).

Where does 13F Pro source HTFL data?

All Heartflow, Inc. fundamentals and ownership data come directly from SEC EDGAR. Heartflow, Inc. files with the SEC under CIK 1464521. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HTFL in?

Heartflow, Inc. (HTFL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HTFL research updated on 13F Pro?

HTFL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Heartflow, Inc.(HTFL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1464521 HTFL stock profile & AI dashboard →

13F Pro Quality Score

45.3/100

Rank #1,728 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

92.7/100

Profitability

30.0/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

94.7/100

Revenue Scale

30.0/100

Dilution Risk

19.7/100

HTFL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Heartflow, Inc. (HTFL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HTFL at 45.3/100 on a 32-signal composite quality model, placing it at rank #1,728 of 2,879 stocks — the bottom half of the AI-ranked universe. HTFL scores in the top quartile across institutional flow (94.7), revenue growth (92.7). Areas of concern include profitability (30.0) and balance sheet strength (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Heartflow, Inc. reports quarterly revenue of $52.6M, net income of $-27.4M, free cash flow of $-32.0M. Top institutional holders of HTFL by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, Bain Capital Life Sciences Investors,, FMR, based on the most recent SEC filings. HTFL trades on the Nasdaq exchange and files with the SEC under CIK 1464521. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HTFL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Heartflow, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$52.6M

Net Income

Q1 2026

$-27.4M

Free Cash Flow

Q1 2026

$-32.0M

ROIC

Q1 2026

-10.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+39.9% YoY

$176.0MFY 2025

FY22 —FY23 $87.2MFY24 $125.8MFY25 $176.0M

Net Income

-21.1% YoY

$-116.8MFY 2025

FY22 —FY23 $-95.7MFY24 $-96.4MFY25 $-116.8M

Operating Income

-4.6% YoY

$-64.1MFY 2025

FY22 —FY23 $-72.9MFY24 $-61.2MFY25 $-64.1M

EPS (Diluted)

-129.2% YoY

$-3.17FY 2025

FY22 —FY23 $-1.95FY24 $-1.38FY25 $-3.17

Total Assets

+202.8% YoY

$359.5MFY 2025

FY22 —FY23 —FY24 $118.7MFY25 $359.5M

Op. Cash Flow

+21.7% YoY

$-54.0MFY 2025

FY22 —FY23 $-76.4MFY24 $-69.0MFY25 $-54.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$176.0M +39.9%	$125.8M +44.3%	$87.2M	—
Net Income	$-116.8M -21.1%	$-96.4M -0.8%	$-95.7M	—
Operating Income	$-64.1M -4.6%	$-61.2M +16.0%	$-72.9M	—
EPS (Diluted)	$-3.17 -129.2%	$-1.38 +29.0%	$-1.95	—
Total Assets	$359.5M +202.8%	$118.7M	—	—
Operating Cash Flow	$-54.0M +21.7%	$-69.0M +9.7%	$-76.4M	—

AI Insight: HTFL Ratio Trends

Operating margin deteriorated sharply to -56.1% in Q1 2026, marking the worst performance in the trailing sequence as losses widened across all profitability metrics.

• Operating margin collapsed from -32.6% in Q3 2025 to -56.1% in Q1 2026, a 23.5pp deterioration in two quarters.

• ROIC worsened from -23.7% in Q3 2025 to -41.3% in Q1 2026, signaling accelerating capital destruction.

• Net profit margin swung from -109.9% in Q3 2025 to -52.1% in Q1 2026, though overall profitability remains deeply negative.

⚠ Operating losses are expanding, not contracting—Q1 2026 represents the worst quarter in the visible sequence.

⚠ ROA fell to -31.8% in Q1 2026 from -27.2% in Q4 2025, indicating deteriorating asset efficiency.

Get alerted when HTFL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Heartflow, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HTFL

WELLINGTON MANAGEMENT GROUP LLP
$291.5M11,982,283 sh
Bain Capital Life Sciences Investors, LLC
$254.2M10,448,158 sh
FMR LLC
$131.3M5,397,802 sh
BAMCO INC /NY/
$93.1M3,827,531 sh
JANUS HENDERSON GROUP PLC
$53.1M2,180,976 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$49.8M2,045,938 sh
Invesco Ltd.
$46.5M1,913,090 sh
VANGUARD CAPITAL MANAGEMENT LLC
$46.1M1,893,495 sh
ALLIANCEBERNSTEIN L.P.
$35.7M1,224,326 sh
BlackRock, Inc.
$35.6M1,462,584 sh

Fund	Value	Shares
WELLINGTON MANAGEMENT GROUP LLP	$291.5M	11,982,283
Bain Capital Life Sciences Investors, LLC	$254.2M	10,448,158
FMR LLC	$131.3M	5,397,802
BAMCO INC /NY/	$93.1M	3,827,531
JANUS HENDERSON GROUP PLC	$53.1M	2,180,976
VANGUARD PORTFOLIO MANAGEMENT LLC	$49.8M	2,045,938
Invesco Ltd.	$46.5M	1,913,090
VANGUARD CAPITAL MANAGEMENT LLC	$46.1M	1,893,495
ALLIANCEBERNSTEIN L.P.	$35.7M	1,224,326
BlackRock, Inc.	$35.6M	1,462,584

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HTFL on your watchlist

Track score changes the day Heartflow, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HTFL a good stock to buy?

13F Pro's AI-powered analysis of Heartflow, Inc. (HTFL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HTFL are available on the HTFL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HTFL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HTFL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Heartflow, Inc.'s investment landscape.